ABVC BioPharma enrolls first subject for ADHD Phase II Part 2 study

ABVC BioPharma announced that the first subject was enrolled at University of California San Francisco Medical Center on June 9, 2023. The UCSF site, led by Professor Keith McBurnett, PhD, Psychiatry UCSF Weill Institute for Neurosciences, joins the five Taiwan sites that have begun patient enrollment for the Company’s ADHD Phase II Part 2 clinical study. The study entitled “A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder, Part II” is a randomized, double-blind, placebo-controlled study involving a total of approximately one hundred patients in the United States and Taiwan. A total of fifty-three (53) participants have been enrolled and forty-three have completed the eight-week study thus far. The Phase II Part 2 study is a continuation of the Phase II Part 1 study of ABV-1505 which was completed successfully by achieving the protocol specified primary end points at UCSF and accepted by the US Food & Drug Administration in October of 2020.